Biote Corp (BTMD)
5.75
-0.09
(-1.54%)
USD |
NASDAQ |
May 17, 16:00
5.86
+0.11
(+1.91%)
Pre-Market: 20:00
Biote Cash from Financing (TTM): -15.55M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | -15.55M |
| December 31, 2023 | -14.38M |
| September 30, 2023 | -15.83M |
| Date | Value |
|---|---|
| June 30, 2023 | -24.53M |
| March 31, 2023 | 64.79M |
| December 31, 2022 | 63.46M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-24.53M
Minimum
Jun 2023
64.79M
Maximum
Mar 2023
9.658M
Average
-14.97M
Median
Cash from Financing (TTM) Benchmarks
| Teladoc Health Inc | 9.252M |
| American Shared Hospital Services | 1.91M |
| Novo Integrated Sciences Inc | 4.668M |
| Astrana Health Inc | 116.87M |
| Cryo-Cell International Inc | -0.7611M |